gap operating margin was 42% of revenue, or 41% excluding a one time pre-tax tariff refund of twenty-eight million dollars. ? Non gap earnings per share grew twenty-five percent to three dollars per share. Core metrics was solid in Q3, taking Da Vinci and I on together, total procedures grew 15%, the installed base of systems grew 13%, and average system utilization increased two percent. Revenue growth of twenty two percent against total procedure growth of fifteen percent reflects our innovation-led strategy and growth in system placements. ? As DaVinci 5, SP, and Ion become a greater proportion of our business, revenue growth benefits from a richer product mix, higher levels of integration, and incremental upgrade volumes. Additionally, the scale and cost advantages we have built allow us to broaden our platform portfolio, reach customers in more geographies, and expand access by lowering the cost of DaVinci surgery. ? The price reductions are concentrated in high volume benign procedures where cost may be a barrier to adoption. Those procedures, particularly outside the US and in ambulatory settings, are where we see the largest opportunity to serve incremental patients. This is a strategic decision to reinvest a portion of the value our innovation creates in lower customer costs where they will have the greatest impact on adoption. ? We believe broader adoption creates more long-term value than near term revenue per procedure. Turning to the clinical side of our business, in the US, total procedures increased 11%, reflecting 10% growth in Da Vinci procedures and 29% growth in Ion procedures. US DaVinci growth of 10% was consistent with the expectations we described in July and reflects in part the 16% growth in the prior year quarter, our most difficult comparison of the ? year. hours procedures and benign gynecology procedures other than hysterectomy continue to leak growth. DaVinci 5 accounted for more than a quarter of US procedures in Q3, up from 13% a year ago, ? and DaVinci 5 systems continue to run at utilization above our XI base. Looking ahead, we believe the breadth of surgeon adoption, the continued expansion of benign general surgery, ? and a growing DaVinci 5 and SP install installed base, together with procedures earlier in adoption, including emergent general surgery, cardiac, and nipple-sparing mastectomy, positions us for durable US procedure growth over the long term. ? In the short term, we continue to monitor the impacts from lower ACA enrollment, changes to Medicaid eligibility, and potential changes to 340B. Outside the US, total and DaVinci procedures grew 20%, with Europe up twenty percent, Asia up nineteen percent, and rest of world geographies up twenty two percent. In Europe, growth was led by the UK, Germany, and Italy. In Asia, India and Taiwan led growth, and Japan procedure growth accelerated, reflecting early signs of a response to the June reimbursement changes. Procedure growth in China was roughly in line with the corporate average, reflecting lower recent capital placements. ? In rest rest of world markets, growth was led by Canada, Australia, and Brazil. Within OUS results, DaVinci adoption for benign procedures continued to accelerate, growing 41% in Q3, up from 37% in Q2 and 34% in Q1, with the strongest growth in hernia repair and colosystectomy. Benign procedures represent over a quarter of our international volume today, and the significant majority of the gap between our current international volumes and the addressable opportunity, which is why they are a focus of our investments. As we build local clinical and economic evidence, a growing number of customers in OUS markets are recognizing the clinical benefits of DaVinci for these procedures, and our tiered system portfolio, including XIR, together with the pricing actions I will describe shortly, provides customers the flexibility to right-size their programs relative to to local reimbursement. Third quarter SP procedure growth was 55%, reflecting accelerated growth in the US of 50% and growth of 40% in Korea, our largest SP market. We now have 487 SP systems installed across 27 countries, and procedures in the 25 markets other than the US and Korea nearly doubled from Q3 last year. Total INA revenue in Quarter three grew 18% to $1.8 billion. DaVinci INA revenue per procedure was approximately $1,860 compared to $1,800 last year, primarily driven by higher SP procedures and DaVinci 5 specific INA, partially offset by procedure mix. With respect to instrument pricing, there are two developments to describe. The first is a set of pricing actions we will implement beginning in the first half of including the expansion of our extended use program announced in May. The second is a policy-driven price reduction in China that starts to take effect next month. As Dave described earlier, customer needs are increasingly segmented. In complex procedures, value comes from innovation and clinical capability. ? In high volume benign procedures such as cholecyssectomy and ingrinal hernia repair, it comes from reliability, efficiency and economics. and that's where our pricing actions are focused. Beginning in the first half of 2027, we will extend the useful lives of a subset of core Endorisk instruments ? on our fourth and fifth generation platforms and introduce volume based pricing. Both lower our customers' costs per procedure. Years of investment in instrument design and manufacturing scale enable us to preserve the quality and reliability customers count ? on. In the US, the extended use instruments require a 510K clearance, which is in process. In China, ? the charge code policy changes we described last quarter will result in a significant reduction in our INA prices in that market beginning in November. We continue to engage with provincial governments on implementation ? and to progress through the green channel process for SP and DaVinci 5. Taken together, we expect these pricing actions and the China price reduction ? to lower DaVinci INA revenue per procedure by approximately 3 to 5% ? on a mixed constant basis once fully implemented, meaning holding procedure, product, and geographic mixed constant to isolate the pricing changes themselves. For reference, that is less than the 7% we estimated when we launched our first extended use program in 2020. ? The accretive dynamics we described last quarter, including forced feedback adoption ? and the mixed shift toward DaVinci 5 and SP are not included and will be positive contributors to INA revenue per procedure. ? In terms of timing, the China reduction takes effect in the fourth quarter, or the extended life instruments, as part of our broader INA pricing actions will roll out by country beginning in the first half of 2027, so the remaining impact will build progressively over 2027 rather than as a step function. Turning to cleared procedure categories that we expect to be future growth drivers, cardiac procedures grew 40% in Q3, and during the quarter, we received CE mark for use of DaVinci 5 in cardiac procedures in Europe. We now estimate that the line of sight cardiac opportunity is between 300,000 and 400,000 procedures a year in the regions we are cleared. Separately, breast surgery grew 42%. Both remain early stage opportunities whose near-term pace is linked to the training of surgeons and the accumulation of clinical evidence, and we are investing in both. Today these procedure volumes are still small relative to our total volume. Turning to capital performance and starting with our DaVinci business, we placed 546 DaVinci systems in quarter three, an increase of 28% compared to 427 systems in Q3 last year. Demand was broad-based across our platform portfolio. 315 DaVinci 5 systems, 87 XI, 65 XAR, 42 SP, and 37X systems. DaVinci 5 placements included 41 in OUS markets, up from 12 last year, as DaVinci 5 becomes available in more countries. In the US, we placed 335 systems, up 27% from the 263 systems placed last year, driven by an increased number of multi-system deals as customers continue to convert to DaVinci 5. Building on our focus on amuletary surgery centers, we installed 18 systems at US ASCs in Q3, including 15 XIR systems. This is an early stage multi-year effort, and placements will be uneven quarter to quarter, but our pipeline of ASC opportunities continues to build, informed by customer familiarity with XIR's capabilities and reliability, and its favorable cost profile. Outside the US, we placed 211 systems, an increase of 29% compared to the 164 systems placed last year. By region, we placed 115 systems in Europe, up 83% from 63 last year, 78 in Asia, up 30% from 60%, and 18 in rest of world countries compared to 41 last year. Rest of world placements tend to be uneven quarter to quarter. Europe's performance reflected our broadening focus with record quarterly placements in Portugal, Turkey, and Austria, and solid growth in Poland, Croatia, and Romania. Across all geographies, we place 37 X systems and 65 XIR systems with purchased ASPs of approximately half a million dollars and $1.2 million respectively, demonstrating our ability and willingness to compete effectively across the broad spectrum of customers and their economic objectives. Over the last three years, we have entered new geographies, including Croatia, Peru, Morocco, and Lithuania, and in 2027 we plan to accelerate our expansion into additional countries we do not serve today. Given increasing investments in OUS markets and planned expansion into new geographies, in January we plan to update our estimate of the long term opportunity in soft tissue surgery. ? We placed a record 42 SP systems in Q3, including 21 in the US and 12 in Korea, ? and the installed base of SP systems increased 42% from the year ago period to 487 systems. For our Ion platform, we placed 56 systems in Q3 compared to 50 systems last year. Given our capital performance, Quarter 3 systems revenue grew 30% to $769 million.
Passages & reports (68) 12:54 gap operating margin was 42% of revenue, or 41% excluding a one time pre-tax tariff refund… Report 13:04 Non Report 13:04 gap earnings per share grew twenty-five percent to three dollars per share. Core metrics w… Report 13:24 Revenue growth of twenty two percent against total procedure growth of fifteen percent ref… Report 13:33 As Report 13:33 DaVinci 5, SP, and Ion become a greater proportion of our business, revenue growth benefit… Report 13:53 in more geographies, and expand access by lowering the cost of DaVinci surgery. Report 13:59 The Report 13:59 price reductions are concentrated in high volume benign procedures where cost may be a bar… Report 14:19 value our innovation creates in lower customer costs where they will have the greatest imp… Report 14:26 We Report 14:26 believe broader adoption creates more long-term value than near term revenue per procedure… Report 14:46 DaVinci growth of 10% was consistent with the expectations we described in July and reflec… Report 14:58 year. Report 15:00 hours procedures and benign gynecology procedures other than hysterectomy continue to leak… Report 15:14 and Report 15:14 DaVinci 5 systems continue to run at utilization above our XI base. Looking ahead, we beli… Report 15:27 and Report 15:27 a growing DaVinci 5 and SP install installed base, together with procedures earlier in ado… Report 15:43 In Report 15:43 the short term, we continue to monitor the impacts from lower ACA enrollment, changes to M… Report 16:03 rest of world geographies up twenty two percent. In Europe, growth was led by the UK, Germ… Report 16:23 roughly in line with the corporate average, reflecting lower recent capital placements. Report 16:29 In Report 16:29 rest rest of world markets, growth was led by Canada, Australia, and Brazil. Within OUS re… Report 16:49 repair and colosystectomy. Benign procedures represent over a quarter of our international… Report 17:09 economic evidence, a growing number of customers in OUS markets are recognizing the clinic… Report 17:29 relative to to local reimbursement. Third quarter SP procedure growth was 55%, reflecting … Report 17:49 countries, and procedures in the 25 markets other than the US and Korea nearly doubled fro… Report 18:09 compared to $1,800 last year, primarily driven by higher SP procedures and DaVinci 5 speci… Report 18:29 half of including the expansion of our extended use program announced in May. The second i… Report 18:49 innovation and clinical capability. Report 18:51 In Report 18:51 high volume benign procedures such as cholecyssectomy and ingrinal hernia repair, it comes… Report 19:10 on Report 19:10 our fourth and fifth generation platforms and introduce volume based pricing. Both lower o… Report 19:27 on. Report 19:28 In the US, the extended use instruments require a 510K clearance, which is in process. In … Report 19:36 the Report 19:36 charge code policy changes we described last quarter will result in a significant reductio… Report 19:49 and Report 19:50 to progress through the green channel process for SP and DaVinci 5. Taken together, we exp… Report 19:59 to Report 19:59 lower DaVinci INA revenue per procedure by approximately 3 to 5% Report 20:04 on Report 20:05 a mixed constant basis once fully implemented, meaning holding procedure, product, and geo… Report 20:22 The Report 20:22 accretive dynamics we described last quarter, including forced feedback adoption Report 20:27 and Report 20:27 the mixed shift toward DaVinci 5 and SP are not included and will be positive contributors… Report 20:36 In Report 20:36 terms of timing, the China reduction takes effect in the fourth quarter, or the extended l… Report 20:56 Turning to cleared procedure categories that we expect to be future growth drivers, cardia… Report 21:15 400,000 procedures a year in the regions we are cleared. Separately, breast surgery grew 4… Report 21:35 volumes are still small relative to our total volume. Turning to capital performance and s… Report 21:55 platform portfolio. 315 DaVinci 5 systems, 87 XI, 65 XAR, 42 SP, and 37X systems. DaVinci … Report 22:15 in more countries. In the US, we placed 335 systems, up 27% from the 263 systems placed la… Report 22:35 amuletary surgery centers, we installed 18 systems at US ASCs in Q3, including 15 XIR syst… Report 22:54 XIR's capabilities and reliability, and its favorable cost profile. Outside the US, we pla… Report 23:14 83% from 63 last year, 78 in Asia, up 30% from 60%, and 18 in rest of world countries comp… Report 23:34 placements in Portugal, Turkey, and Austria, and solid growth in Poland, Croatia, and Roma… Report 23:54 ability and willingness to compete effectively across the broad spectrum of customers and … Report 24:13 countries we do not serve today. Given increasing investments in OUS markets and planned e… Report 24:28 We Report 24:29 placed a record 42 SP systems in Q3, including 21 in the US and 12 in Korea, Report 24:35 and Report 24:36 the installed base of SP systems increased 42% from the year ago period to 487 systems. Fo… Report 24:55 30% to $769 million. Report